Previous Statements by BMRN
» BioMarin Pharmaceutical's CEO Discusses Q4 2011 Earning Results - Earnings Call Transcript
» BioMarin Pharmaceutical Presents at 30th Annual JP Morgan Healthcare Conference (Transcript)
» BioMarin Pharmaceutical's CEO Discusses Q3 2011 Results - Earnings Call Transcript
And now I'd like to turn the call over to J.J., BioMarin's CEO.Jean-Jacques Bienaimé Thank you, Eugenia. Good afternoon, and thank you for joining us on today's call. So I have as usual a few introductory comments before Jeff reviews the financials for the first quarter and Hank provides an update on our research and development programs. And then Steve will provide more details on our commercial portfolio before we open the call for questions. So we are very pleased with the progress we have made in the first quarter and we believe we're off to a strong start in 2012. Starting with our commercial portfolio, we exceeded $100 million in quarterly revenues for BioMarin marketed products for the first time in Q1 of this year. This was driven by a year-over-year increase in Naglazyme net product revenue of 13%, and that despite a weaker euro than last year and a year-over-year increase in equivalent net product revenues of 20%. As we have communicated previously in early January, we booked an order from Brazil that was delayed from Q4 2011. But even without this order, Q1 would have been our strongest Naglazyme quarter since March. Jeff will explain. Net product transfer revenue had a negative $6.4 million impact on net Aldurazyme revenue to BioMarin. And despite the negative effect of product transfer revenue, we will receive $18.4 million of royalties in cash from Genzyme for this quarter. And had product transfer revenue been neutral in Q1, total BioMarin revenue would have been $123 million. Net of Aldurazyme product revenue is expected to be neutral or positive in Q2 and positive in the second half of the year. More importantly, the total number of Aldurazyme treated patients keeps growing with a 9.1% increase in the first quarter of 2012 as compared to the first quarter of 2011.
Also, the number of patients treated with Naglazyme continues to increase steadily during the same period, and we are in a trajectory to reach top sales well above $300 million.Following this record quarter in both Naglazyme sales and the number of patients treated, we decided to increase the lower end of our Naglazyme guidance -- revenue guidance by $10 million for the whole 2012 year. Our cash balance were $288 million at the end of the first quarter, down slightly from $290 million at the end of 2011. Our R&D pipeline remains our top priority for 2012. We are on track for 5 significant clinical readouts by the end of the year, including the Phase III trial for GALNS, the Phase II trial for PEG-PAL, the Phase I/II trial for BMN-701 for Pompe disease, the Phase I/II trial for BMN-673 for solid tumors and the Phase I trials in healthy volunteers for BMN-111 for achondroplasia. Positive results for one or more of these patients-based trials could be transformative for the company. Our increased R&D spend in the first quarter is linked primarily to clinical manufacturing costs and enrollment of an additional 16 patients in the GALNS Phase III trial as compared to our initial objectives because of the overwhelming enthusiasm for the study in the Morquio community. Also please keep in mind that almost 20% of our projected R&D spend of $265 million to $275 million in 2012 is totally for direct supply. If Phase III GALNS is approved, approximately $7 million of expenses from the manufacturing campaign in 2012 who would support named patient and commercial sales in the future, so the spend -- some of the spend is actually an investment in working capital. Also despite the expectations for higher R&D spend, our projected net income remains unchanged. Read the rest of this transcript for free on seekingalpha.com